Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin’s lymphoma and multiple myeloma: results from the expanded access program
Paul Shaughnessy(CHRISTUS Transplant Institute), Peter A. McSweeney(Mesoblast (United States)), John M. McCarty(Virginia Commonwealth University), Patrick J. Stiff(Loyola University Medical Center), David G. Johns(Marine Biological Association of the United Kingdom), Robin Joyce(Beth Israel Deaconess Medical Center), R.B. Berryman(Baylor University), Ivana N. Micallef(Mayo Clinic), Frank J. Hsu(Sanofi (France)), Andrew Artz, Eric D. Jacobsen(Dana-Farber Cancer Institute), R. Maziarz(Oregon Health & Science University), J. M. Vose(University of Nebraska Medical Center), Joseph P. Uberti(Sheba Medical Center), Michael J. Dugan(Indiana Cancer Consortium), Edward D. Ball(Sheba Medical Center), Steven M. Devine(National Marrow Donor Program)
Cited by 35
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k